Ann: Quarterly Activity Report & Appendix 4C, page-7

The timing of orders and payments will not align nicely with each quarterly period. We need a longer stretch to judge the rate of uptake of Striate and Remplir.

Meanwhile, the company is focused on building strong foundations - that's what matters for me. Like some others, I've made a sizeable investment in Orthocell, and my main concern is that my money is safe. Rapid growth would be great - and that may come at some point - but steady progress toward the really big markets is what I'm looking for.

On the Orthocell website, in the investor section, there is a lot of useful information - including the recent Veritas report - but also the highlighted reminder that, "Orthocell is pursuing a total addressable market for our dental, nerve and autologous tendon Therapy Products of US$17 billion dollars per annum..."

I like what they are pursuing.